Lightcast Discovery closes £1.3m Seed round
Lightcast Discovery, was spun out of OTIF portfolio company Base4 Innovation in early 2019 to develop a next-generation microfluidic platform to revolutionise complex cell analysis. Today it announced the close of a £1.3m Seed round with investment from OTIF and other private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.
Originating from work carried out by the founders at Base4 in Cambridge, Lightcast Discovery has attracted substantial interest from major pharma companies and leading academic groups, and is engaged in collaborative studies across a variety of applications. The platform offers game-changing capabilities in a wide range of fields including drug discovery, cell therapy, antibody/biologic discovery, CRISPR screening, immuno-oncology, cell line development, stem cells, and synthetic biology.
Click here for the official company free release